Department of Biopharmaceutics, School of Pharmacy, No. 103 of Wenhua Road, Shenyang 110016, PR China.
Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):262-72. doi: 10.2174/157489209789206869.
Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nab-technology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
白蛋白是一种在抗肿瘤药物输送系统中用途广泛的药物载体，它对肿瘤也具有主动靶向能力。最近，纳米颗粒白蛋白结合（nab）紫杉醇（nab-紫杉醇；Abraxane）于 2006 年被批准用于联合化疗失败的转移性乳腺癌患者，因此 nab 技术在抗肿瘤药物输送系统中引起了广泛关注。本文讨论了 nab-紫杉醇（ABI-007）的制备、表征和评价的详细信息。还综述了 ABI-007 的药代动力学、药效学和临床试验。此外，还通过与 nab 技术相关的专利，总结了 nab 技术在抗肿瘤药物输送系统中的最新应用。总之，为了获得更好的安全性和治疗效果，nab 技术在未来抗肿瘤药物输送领域具有广泛的应用潜力。
